A Spanish biotech banks $87M to make differentiated ADCs

🇪🇸 BioPharma Dive (ES) —
A Spanish biotech banks $87M to make differentiated ADCs

AI Summary

Ona Therapeutics, a biotechnology company based in Barcelona, Spain, has secured $87 million in funding to develop next-generation Antibody-Drug Conjugates (ADCs). The company aims to create differentiated treatments for advanced breast and colorectal cancers to aid patient outcomes.

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.

Deals Health biotech funding anticancer drugs ADCs Barcelona Ona Therapeutics breast cancer colorectal cancer

Read original source →